Navigation Links
Deep brain stimulation shows promising results for unipolar and bipolar depression
Date:1/2/2012

ATLANTAA new study shows that deep brain stimulation (DBS) is a safe and effective intervention for treatment-resistant depression in patients with either unipolar major depressive disorder (MDD) or bipolar ll disorder (BP). The study was published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.

The study was led by Helen S. Mayberg, MD, professor in the Departments of Psychiatry and Behavioral Sciences and Neurology at Emory University School of Medicine, with co-investigators Paul E. Holtzheimer, MD, lead psychiatrist and now associate professor and director of the Mood Disorders Service, Dartmouth Medical School, and neurosurgeon Robert E. Gross, MD, PhD, associate professor in the Departments of Neurosurgery and Neurology at Emory. Gross served as chief neurosurgeon for the study.

"Depression is a serious and debilitating medical illness," says Mayberg. "When we found that the potential for effective and sustained antidepressant response with DBS for patients with otherwise treatment resistant major depressive disorder was high, the next step was to determine if patients with intractable bipolar depression could also be successfully treated."

An earlier study by Mayberg done in Toronto in collaboration with scientists at Toronto Western Hospital, University Health Network and Emory, was the first to show such results for patients with treatment-resistant major depressive disorder. Mayberg conducted this new expanded trial at Emory to include patients with bipolar ll disorder.

Bipolar spectrum disorder, sometimes referred to as manic-depression, is characterized by bouts of mania or hypomania alternating between episodes of depression. Although people with bipolar ll disorder do not have full manic episodes, depressive episodes are frequent and intense, and there is a high risk of suicide. A major challenge in treating bipolar depression is that many antidepressant medications may cause patients to "switch" into a hypomanic or manic episode.

DBS uses high-frequency electrical stimulation targeted to a predefined area of the brain specific to the particular neuropsychiatric disorder. Here, each study participant was implanted with two thin wire electrodes, one on each side of the brain. The other end of each wire was connected under the skin of the patient's neck to a pulse generator implanted in the chest similar to a pacemaker that directs the electrical current.

Study participants received single-blind stimulation for four weeks (patients did not know if the DBS system was on or off), followed by active stimulation for 24 weeks. Patients were evaluated for up to two years following onset of active stimulation. Seventeen patients were enrolled in the study.

A significant decrease in depression and increase in function were associated with continuing stimulation. Remission and response rates were 18 percent and 41 percent after 24 weeks; 36 percent and 36 percent after one year and 58 percent and 92 percent after two years of active stimulation. Patients who achieved remission did not experience a spontaneous relapse. Efficacy was similar for Major Depressive Disorder and Bi-Polar patients, and no participant experienced a manic or hypomanic episode.

Mayberg and her colleagues continue to refine this intervention. Current studies include demographic, clinical and imaging predictors of response and remission, and introduction of psychotherapeutic rehabilitation. Why and how this treatment works is the primary focus of ongoing research.

"Most of these patients have been in a depressed state for many years and are disabled and isolated," says Holtzheimer. "As their depression improves, they need a process to help them achieve full recovery that includes integration back into society.

"We hope to optimize the rate of improvement for these patients by using a model of care that provides psychotherapeutic rehabilitation built on evidence-based psychotherapy but tailored to the specific individual's situation."


'/>"/>

Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
Emory University
Source:Eurekalert

Related biology news :

1. Penn biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
2. During exercise, the human brain shifts into high gear on alternative energy
3. Millisecond brain signals predict response to fast-acting antidepressant
4. Food for thought -- regulating energy supply to the brain during fasting
5. Risk and reward compete in brain
6. Brainy genes, not brawn, key to success on mussel beach
7. Brain-nourishing molecule may predict schizophrenia relapse
8. Brain structure provides key to unraveling function of bizarre dinosaur crests
9. MU brain imaging center provides research for autism, schizophrenia and Parkinsons disease
10. Key to function of dinosaur crests found in brain structure
11. Emotion and scent create lasting memories -- even in a sleeping brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... West Point, IA (PRWEB) , ... January 17, ... ... approval from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance ... tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 ... when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
Breaking Biology Technology: